leadf
logo-loader

IPO Roundup: NASH treatment developer 89bio ready to go public following brief IPO delay

Last week, the company opted to postpone its $70 million IPO after an administrative issue arose between its auditor and the SEC

Doctor holding a model liver
NASH biotechs to go public since 2014 have averaged 1% return on their first day of trading and -25% return overall, according to data from research firm Renaissance Capital

89bio Inc (NASDAQ:ETNB), a Phase 1 biotechnology company developing therapies for non-alcoholic steatohepatitis (NASH), is back this week after a false start. 

Last week, the company opted to postpone its $70 million IPO after an administrative issue arose between its auditor and the SEC. 

The San Francisco company plans to offer 4.4 million shares at between $15 and $17 per share. 

NASH represents a multi-billion market

89bio’s company’s lead product candidate, BIO89-100, is an engineered analog of fibroblast growth factor 21, which functions as an endocrine hormone-regulating carbohydrate and lipid metabolism.

With no FDA-approved therapy, treatment for NASH represents a multi-billion dollar market, but 89bio is far from the only horse in the race. 

Akero Therapeutics Inc (NASDAQ:AKRO) and NGM Biopharmaceuticals Inc (NASDAQ:NGM) went public this year in June and April, respectively. Akero is up about 24% overall, and NGM has dipped more than 20%

NASH biotechs to go public since 2014 have averaged 1% return on their first day of trading and -25% return overall, according to research firm Renaissance Capital.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Cabral Gold adds 2nd drill rig as company identifies new high-grade veins

Cabral Gold (CVE: CBR-OTC: CBGZF) CEO Alan Carter joined Steve Darling from Proactive Vancouver with news the company has identified at least six new NE trending high-grade veins in the Machichie SW area located immediately north of the MG deposit. Carter telling Proactive what had led them...

16 hours, 2 minutes ago

2 min read